Skip to main content

Table 2 Comparison of treatment eligibility criteria among treatment-naïve chronic hepatitis B patients, Ethiopia (N = 271)

From: Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

St. Paul EASL 2012 EASL 2017 WHO 2015
Criteria N Criteria N Criteria N Criteria N
Decompensated cirrhosis 20 Cirrhosis and detectable VL 40 Cirrhosis and detectable VL 40 Decompensated cirrhosis 20
Compensated cirrhosis 20 Significant fibrosis and VL >2000 IU/ml 8 Significant fibrosis and VL >2000 IU/ml 8 APRI >2.0a 4
Significant fibrosis and VL >2000 IU/ml 8 ALT >80 U/L and VL >20,000 IU/ml 1 ALT >80 U/L and VL >20,000 IU/ml 1 Age ≥ 30 years and ALT >40 U/L and VL >20,000 IU/ml 5
ALT >80 U/L and VL >2000 IU/ml 3 Metavir ≥A2 and VL >2000 IU/mlb 0 Metavir ≥A2 and VL >2000 IU/mlb 0   
Family history HCC and VL >2000 IU/ml 5    HBeAg positive and age ≥ 30 years 3   
     Family history HCC or cirrhosis 16   
Total 56 Total 49 Total 68 Total 29
  1. ALT alanine aminotransferase, VL viral load, HCC hepatocellular carcinoma, APRI aspartate aminotransferase to platelet ratio index
  2. aPlatelet counts were missing and APRI could not be calculated in 20 patients
  3. bLiver biopsy was not performed; hence, none fulfilled this criterion